Recent advances in therapies for primary myelofibrosis
Primary myelofibrosis (PMF), polycythemia vera (PV) and essential thrombocythemia (ET) form the classical BCR-ABL1-negative myeloproliferative neoplasms (MPNs) that are driven by a constitutive activation of JAK2 signaling. PMF as well as secondary MF (post-ET and post-PV MF) are the most aggressive...
Κύριοι συγγραφείς: | Vainchenker, W, Yahmi, N, Havelange, V, Marty, C, Plo, I, Constantinescu, SN |
---|---|
Μορφή: | Journal article |
Γλώσσα: | English |
Έκδοση: |
Faculty Opinions
2023
|
Παρόμοια τεκμήρια
Παρόμοια τεκμήρια
-
Recent advances in understanding myelofibrosis and essential thrombocythemia [version 1; referees: 2 approved]
ανά: William Vainchenker, κ.ά.
Έκδοση: (2016-04-01) -
Therapeutic activity of GARP:TGF-β1 blockade in murine primary myelofibrosis
ανά: Lecomte, S, κ.ά.
Έκδοση: (2023) -
ADVANCED THERAPY IN PATIENTS WITH PRIMARY AND POSTPOLYCYTHEMIC MYELOFIBROSIS
ανά: A. N. Alekseeva, κ.ά.
Έκδοση: (2017-07-01) -
Molecular pathogenesis of myeloproliferative neoplasms: Where do we stand in 2023?
ανά: Havelange, V, κ.ά.
Έκδοση: (2023) -
Recent developments in myelofibrosis
ανά: Mesa RA, κ.ά.
Έκδοση: (2012-07-01)